Moleculin's Annamycin shows no cardiotoxicity at high doses in ASCO data

Moleculin presented pooled analysis of 90 patients showing no detectable cardiotoxicity with Annamycin despite cumulative exposure levels far exceeding conventional anthracycline limits, with independent Cleveland Clinic validation. The positive cardiac safety data support the company's MIRACLE Phase 2b/3 trial advancement and potential best-in-class positioning for the lead drug candidate.